Coronary Stenosis - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 20

Coronary Stenosis – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Coronary Stenosis - Pipeline Review, H2 2012', provides an overview of the Coronary Stenosis therapeutic pipeline. This report provides information on the therapeutic development for Coronary Stenosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Coronary Stenosis. 'Coronary Stenosis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Coronary Stenosis.
- A review of the Coronary Stenosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Coronary Stenosis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Coronary Stenosis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Coronary Stenosis pipeline depth and focus of Coronary Stenosis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Coronary Stenosis Therapeutic Products under Development, Key Players in Coronary Stenosis Therapeutics, Coronary Stenosis Pipeline Overview, Coronary Stenosis Pipeline, Coronary Stenosis Pipeline Assessment

2
List of Tables 3
List of Figures 3
Introduction 4
REPORT COVERAGE 4
Coronary Stenosis Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Coronary Stenosis 6
Coronary Stenosis Therapeutics under Development by Companies 8
Mid Clinical Stage Products 9
Comparative Analysis 9
Coronary Stenosis Therapeutics – Products under Development by Companies 10
Companies Involved in Coronary Stenosis Therapeutics Development 11
Coronary Stenosis – Therapeutics Assessment 11
Assessment by Monotherapy Products 11
Assessment by Route of Administration 12
Assessment by Molecule Type 14
Drug Profiles 16
Liposomal Alendronate - Drug Profile 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Coronary Stenosis Therapeutics – Discontinued Products 17
Coronary Stenosis Therapeutics - Dormant Products 18
Appendix 19
Methodology 19
Coverage 19
Secondary Research 19
Primary Research 19
Expert Panel Validation 19
Contact Us 20
Disclaimer 20

List of Tables
Number of Products Under Development for Coronary Stenosis, H2 2012 6
Products under Development for Coronary Stenosis – Comparative Analysis, H2 2012 7
Number of Products under Development by Companies, H2 2012 8
Comparative Analysis by Mid Clinical Stage Development, H2 2012 9
Products under Development by Companies, H2 2012 10
Assessment by Monotherapy Products, H2 2012 11
Assessment by Stage and Route of Administration, H2 2012 13
Assessment by Stage and Molecule Type, H2 2012 15
Coronary Stenosis Therapeutics – Discontinued Products 17
Coronary Stenosis Therapeutics – Dormant Products 18

List of Figures
Number of Products under Development for Coronary Stenosis, H2 2012 6
Products under Development for Coronary Stenosis – Comparative Analysis, H2 2012 7
Products under Development by Companies, H2 2012 8
Mid Clinical Stage Products, H2 2012 9
Assessment by Monotherapy Products, H2 2012 11
Assessment by Route of Administration, H2 2012 12
Assessment by Stage and Route of Administration, H2 2012 13
Assessment by Molecule Type, H2 2012 14
Assessment by Stage and Molecule Type, H2 2012 15

Customers who bought this item also bought

• Acute Coronary Syndrome - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Smoking Cessation - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Osteoarthritis - Pipeline Review, H2 2012
• Type 2 Diabetes - Pipeline Review, H2 2012